In accordance with the western Sweden series, patients with FGL2‐positive GIST had superior RFS as compared to those whose GIST did not express FGL2 in the SSGXVIII series (HR = 0.64, 95% CI: 0.44–0.95; p = 0.026), but there was no significant association between GIST FGL2 expression and overall survival (p = 0.298; Figure 2D‐E). Here, FGL2 is linked to gastrointestinal stromal tumor.